The U.S. FDA recently approved ALPHA-1062 (Zunveyl®) by Alpha Cognition Inc. for treating mild-to-moderate Alzheimer’s disease, which affects 6.7 million Americans.
Many physicians are unsatisfied with current Alzheimer’s therapies due to side effects and limited effectiveness, leading to patient discontinuation of treatment.
The mechanism of action for Acetylcholinesterase (AChE) involves critical sites such as the anionic and esteratic sites, crucial for neurotransmitter regulation at synaptic junctions.
AChE is targeted in Alzheimer’s treatment to increase acetylcholine concentrations, potentially improving cognitive functions like memory and learning.
Sino Biological offers AChE proteins and antibodies to study AChE’s role in Alzheimer’s disease, supporting drug discovery and diagnostics development.
In a significant development in the field of Alzheimer’s disease treatment, the U.S. FDA has recently approved a new drug called ALPHA-1062 by Alpha Cognition Inc. This medication, also known as Zunveyl®, is an Acetylcholinesterase (AChE) inhibitor designed to address mild-to-moderate cases of Alzheimer’s disease, a condition impacting around 6.7 million individuals in the United States. With a high level of dissatisfaction among physicians towards current therapies due to side effects and limited effectiveness, the approval of ALPHA-1062 offers new hope for patients and healthcare providers.
AChE plays a crucial role in regulating neurotransmitter levels in the brain, particularly in processes related to memory, learning, and muscle contraction. Targeting AChE as a drug target in Alzheimer’s disease management aims to increase acetylcholine concentrations, potentially improving cognitive function and alleviating symptoms associated with the condition. Supporting this research, Sino Biological Inc. offers essential tools such as recombinant AChE proteins and specific antibodies to aid in understanding the enzyme’s functions and interactions, ultimately contributing to the advancement of drug discovery and diagnostic efforts for Alzheimer’s disease and other neurodegenerative disorders.
